Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIME-MINOR
NCT07476898Phase 3Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Proportion of patients with a modified Rankin Scale score of 0-1 at 90 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07476898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476898.